AbbVie Net Worth 2010-2022 | ABBV

Interactive chart of historical net worth (market cap) for AbbVie (ABBV) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. AbbVie net worth as of January 26, 2023 is $260.67B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $260.674B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $441.560B 16.62
Eli Lilly (LLY) United States $330.671B 41.73
Novo Nordisk (NVO) Denmark $311.249B 40.81
Merck (MRK) United States $270.958B 13.95
Pfizer (PFE) United States $248.389B 6.79
Novartis AG (NVS) Switzerland $198.780B 14.97